These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34175104)

  • 21. Cutting edges in Clostridioides difficile infections.
    Durovic A; Tschudin-Sutter S
    Swiss Med Wkly; 2021 Sep; 151():w30033. PubMed ID: 34652093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with solid organ transplants: an institutional experience and review of the literature.
    Lin SC; Alonso CD; Moss AC
    Transpl Infect Dis; 2018 Dec; 20(6):e12967. PubMed ID: 30011107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microbiologic factors affecting Clostridium difficile recurrence.
    Chilton CH; Pickering DS; Freeman J
    Clin Microbiol Infect; 2018 May; 24(5):476-482. PubMed ID: 29208562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in
    Khanna S
    Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1067-1070. PubMed ID: 33427531
    [No Abstract]   [Full Text] [Related]  

  • 25. Bezlotoxumab use as adjunctive therapy with the third fecal microbiota transplant in refractory recurrent Clostridium difficile colitis; a case report and concise literature review.
    Kaako A; Al-Amer M; Abdeen Y
    Anaerobe; 2019 Feb; 55():112-116. PubMed ID: 30521856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fecal microbiota transplant for C. difficile infection: Just say yes.
    Cammarota G; Gallo A; Bibbò S
    Anaerobe; 2019 Dec; 60():102109. PubMed ID: 31644957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful Therapy of Severe Pseudomembranous Clostridium difficile Colitis Using a Combination of Fecal Microbiota Therapy and Fidaxomicin.
    Konturek PC; Haziri D; Helfritzsch H; Hess T; Harsch IA
    Med Princ Pract; 2017; 26(2):182-184. PubMed ID: 27978522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clostridium difficile infection: review.
    Czepiel J; Dróżdż M; Pituch H; Kuijper EJ; Perucki W; Mielimonka A; Goldman S; Wultańska D; Garlicki A; Biesiada G
    Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1211-1221. PubMed ID: 30945014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical Care Management of the Patient with Clostridioides difficile.
    Adelman MW; Woodworth MH; Shaffer VO; Martin GS; Kraft CS
    Crit Care Med; 2021 Jan; 49(1):127-139. PubMed ID: 33156122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microbiota or placebo after antimicrobial therapy for recurrent
    Drekonja DM; Shaukat A; Zhang JH; Reinink AR; Nugent S; Dominitz JA; Davis-Karim A; Gerding DN; Kyriakides TC
    Clin Trials; 2021 Oct; 18(5):622-629. PubMed ID: 34154439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
    Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
    Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Fecal microbiota transplantation in recurrent Clostridium difficile infection. Report of one case].
    Moscoso F; Simian D; Rivera D; Acuña G; Quera R
    Rev Med Chil; 2015 Apr; 143(4):531-5. PubMed ID: 26204547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current and future trends in clostridioides (clostridium) difficile infection management.
    Khanna S; Gerding DN
    Anaerobe; 2019 Aug; 58():95-102. PubMed ID: 31054313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrent
    Song JH; Kim YS
    Gut Liver; 2019 Jan; 13(1):16-24. PubMed ID: 30400734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of adult Clostridium difficile digestive contaminations: a literature review.
    Mathias F; Curti C; Montana M; Bornet C; Vanelle P
    Eur J Clin Microbiol Infect Dis; 2019 Feb; 38(2):209-231. PubMed ID: 30498879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention and treatment of recurrent Clostridioides difficile infection.
    Shin JH; Warren CA
    Curr Opin Infect Dis; 2019 Oct; 32(5):482-489. PubMed ID: 31369420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
    Orenstein R; Dubberke ER; Khanna S; Lee CH; Yoho D; Johnson S; Hecht G; DuPont HL; Gerding DN; Blount KF; Mische S; Harvey A
    BMC Infect Dis; 2022 Mar; 22(1):245. PubMed ID: 35279084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on Treatment of Clostridioides difficile Infection.
    Cho JM; Pardi DS; Khanna S
    Mayo Clin Proc; 2020 Apr; 95(4):758-769. PubMed ID: 32247350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Fecal microbiota transplant in the treatment of recurrent Clostridium difficile infection: A case report].
    Haemers I; Delvallée M
    Rev Med Brux; 2016; 37(3):174-177. PubMed ID: 28525191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical practice guidelines for Clostridioides (Clostridium) difficile infection and fecal microbiota transplant protocol - recommendations of the Polish Society od Epidemiology and Infectious Diseases.
    Piekarska A; Panasiuk A; Stępień PM
    Przegl Epidemiol; 2020; 74(1):69-87. PubMed ID: 32500988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.